AstraZeneca (LON:AZN – Get Rating)’s stock had its “overweight” rating reissued by equities research analysts at Morgan Stanley in a note issued to investors on Wednesday, Marketbeat.com reports.
Several other brokerages also recently weighed in on AZN. Berenberg Bank reaffirmed a “buy” rating and issued a £120 ($147.95) target price on shares of AstraZeneca in a research report on Friday, May 6th. The Goldman Sachs Group set a GBX 6,950 ($85.69) price target on AstraZeneca in a report on Friday, April 29th. Credit Suisse Group set a £110 ($135.62) price target on AstraZeneca in a report on Tuesday, May 3rd. UBS Group set a £105 ($129.45) price target on AstraZeneca in a report on Monday, March 7th. Finally, Deutsche Bank Rese… set a £115 ($141.78) price target on AstraZeneca in a report on Tuesday, May 3rd. One research analyst has rated the stock with a sell rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of £104.75 ($129.14).
Shares of LON AZN opened at £100.99 ($124.51) on Wednesday. AstraZeneca has a 1-year low of GBX 7,642 ($94.22) and a 1-year high of £110 ($135.62). The business has a 50-day moving average of £100.31 and a 200-day moving average of GBX 9,144.10. The company has a debt-to-equity ratio of 90.06, a current ratio of 1.00 and a quick ratio of 0.65. The company has a market capitalization of £156.48 billion and a price-to-earnings ratio of 1,606.03.
AstraZeneca Company Profile (Get Rating)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.